España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Atossa Therapeutics
ATOS
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.9637
-0.02
-1.66%
At close: -
$0.9901
0.03
2.74%
After Hours: Dec 20, 7:36 PM EDT
Get Report
Comment
Atossa Therapeutics (ATOS) Forecast
News
Earnings
Atossa Therapeutics (ATOS) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Atossa Therapeutics (NASDAQ:ATOS) Stock
Atossa Therapeutics Stock (NASDAQ: ATOS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, December 13, 2024
HC Wainwright & Co. Reiterates Buy on Atossa ...
Benzinga Newsdesk
Thursday, December 12, 2024
HC Wainwright & Co. Reiterates Buy on Atossa ...
Benzinga Newsdesk
Atossa Therapeutics To Present Data Describin...
Benzinga Newsdesk
Wednesday, December 11, 2024
Atossa Therapeutics Reports Phase 2 KARISMA-E...
Benzinga Newsdesk
Tuesday, December 10, 2024
Atossa Therapeutics To Present Pharmacokineti...
Benzinga Newsdesk
Monday, December 09, 2024
Atossa Therapeutics Presents Data From Study ...
Benzinga Newsdesk
Ascendiant Capital Maintains Buy on Atossa Th...
Benzinga Newsdesk
Wednesday, November 20, 2024
Atossa Therapeutics To Present Five Abstracts...
Benzinga Newsdesk
Wednesday, November 13, 2024
HC Wainwright & Co. Maintains Buy on Atossa T...
Benzinga Newsdesk
Tuesday, November 12, 2024
Atossa Therapeutics Q3 EPS $(0.06), Inline
Benzinga Newsdesk
Tuesday, November 05, 2024
HC Wainwright & Co. Reiterates Buy on Atossa ...
Benzinga Newsdesk
Monday, November 04, 2024
Atossa Therapeutics Reports Phase 2 Data for ...
Benzinga Newsdesk
Thursday, October 31, 2024
HC Wainwright & Co. Reiterates Buy on Atossa ...
Benzinga Newsdesk
Atossa Therapeutics Releases Preliminary Anal...
Benzinga Newsdesk
Wednesday, September 11, 2024
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
Avi Kapoor
Ascendiant Capital Maintains Buy on Atossa Th...
Benzinga Newsdesk
Tuesday, September 10, 2024
Atossa Therapeutics Announces Support Of Fina...
Benzinga Newsdesk
Wednesday, August 28, 2024
Atossa Therapeutics Granted New Patent Direct...
Benzinga Newsdesk
Wednesday, August 21, 2024
Atossa Therapeutics And Quantum Leap Healthca...
Benzinga Newsdesk
Monday, August 12, 2024
HC Wainwright & Co. Reiterates Buy on Atossa ...
Benzinga Newsdesk
Atossa Therapeutics Q2 EPS $(0.05) Beats $(0....
Benzinga Newsdesk
Monday, July 22, 2024
Atossa Therapeutics Completes Enrollment Of 8...
Benzinga Newsdesk
Tuesday, July 02, 2024
Atossa Therapeutics Appoints Heather Rees As ...
Benzinga Newsdesk
Friday, June 28, 2024
HC Wainwright & Co. Reiterates Buy on Atossa ...
Benzinga Newsdesk
Atossa Therapeutics Announces Updated Protoco...
Benzinga Newsdesk
Thursday, June 20, 2024
Cantor Fitzgerald Reiterates Overweight on At...
Benzinga Newsdesk
Monday, June 17, 2024
Atossa To Join Russell 3000 Index
Benzinga Newsdesk
Thursday, June 06, 2024
Ascendiant Capital Maintains Buy on Atossa Th...
Benzinga Newsdesk
Wednesday, May 15, 2024
Atossa Therapeutics Last Patient Its Phase 2 ...
Benzinga Newsdesk
Tuesday, May 14, 2024
Cantor Fitzgerald Reiterates Overweight on At...
Benzinga Newsdesk
Monday, May 13, 2024
HC Wainwright & Co. Maintains Buy on Atossa T...
Benzinga Newsdesk
Atossa Therapeutics Q1 2024 Adj EPS $(0.05) B...
Benzinga Newsdesk
Tuesday, May 07, 2024
Atossa Therapeutics Announces Support Of New ...
Benzinga Newsdesk
Monday, April 29, 2024
Atossa Therapeutics Announces Expanded Resear...
Benzinga Newsdesk
Tuesday, April 16, 2024
HC Wainwright & Co. Reiterates Buy on Atossa ...
Benzinga Newsdesk
Monday, April 15, 2024
Atossa Therapeutics And Quantum Leap Healthca...
Benzinga Newsdesk
Tuesday, April 09, 2024
Atossa Therapeutics Presents Data From 40mg C...
Benzinga Newsdesk
Tuesday, April 02, 2024
HC Wainwright & Co. Maintains Buy on Atossa T...
Benzinga Newsdesk
Tuesday, March 19, 2024
Atossa Therapeutics shares are trading higher...
Benzinga Newsdesk
Atossa Therapeutics Provides Five-Year (Z)-En...
Benzinga Newsdesk
Monday, March 18, 2024
Atossa Therapeutics Regains Compliance With N...
Benzinga Newsdesk
Wednesday, March 06, 2024
Data From Atossa's Phase 2 EVANGELINE Clinica...
Benzinga Newsdesk
Thursday, February 22, 2024
Atossa Therapeutics Announces First Patient D...
Benzinga Newsdesk
Monday, February 12, 2024
HC Wainwright & Co. Initiates Coverage On Ato...
Benzinga Newsdesk
Wednesday, February 07, 2024
Atossa Therapeutics Fully Enrolls (Z)-Endoxif...
Benzinga Newsdesk
Tuesday, January 09, 2024
Atossa Therapeutics Issues Letter To Sharehol...
Benzinga Newsdesk
Monday, November 20, 2023
Atossa Therapeutics Announces Full Enrollment...
Benzinga Newsdesk
Thursday, November 16, 2023
Atossa Therapeutics Board Member Awarded $42K Worth of Stock Options
Benzinga Insights
Director at Atossa Therapeutics Acquires Company Stock Options Worth 62,500 Shares
Benzinga Insights
Monday, November 13, 2023
Atossa Therapeutics Q3 EPS $(0.05) Beats $(0....
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch